|
 The Department of Health and Human Services (HHS) filed a notice of
appeal on Wednesday, as it prepares to challenge the July federal
court ruling.
"If the drug companies are embarrassed by their prices or afraid
that the prices will scare patients away, they should lower them,"
said Caitlin Oakley, a spokeswoman for HHS.
In his ruling, U.S. District Judge Amit Mehta in Washington said
that HHS lacked the authority from U.S. Congress to compel drug
manufacturers to disclose list prices.
The administration issued the rule in May.
The rule, which applied to drugs with list prices exceeding $35 for
a one-month supply, is part of a broader push by President Donald
Trump to lower drug prices.
[to top of second column] |
HHS said in July that it and the U.S. Food and Drug Administration
will propose a rule that will allow it to authorize states and other
groups to pursue pilot projects related to importing drugs from
Canada.
Reuters has previously reported that the administration is
considering broadening its plans to link the cost of some drugs for
the government Medicare program to an international pricing index.
(Reporting by Carl O'Donnell; Editing by Sonya Hepinstall)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
